Alfonso Pérez
About
Alfonso Pérez is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Molecular Biology.
According to data from OpenAlex, Alfonso Pérez has authored 69 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Cardiology and Cardiovascular Medicine and 14 papers in Molecular Biology. Recurrent topics in Alfonso Pérez's work include Diabetes Treatment and Management (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers) and Computational Drug Discovery Methods (12 papers). Alfonso Pérez is often cited by papers focused on Diabetes Treatment and Management (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers) and Computational Drug Discovery Methods (12 papers). Alfonso Pérez collaborates with scholars based in United States, Spain and Japan. Alfonso Pérez's co-authors include Ralph B. D’Agostino, Steven M. Haffner, Stuart Kupfer, Theodore Mazzone, Steven B. Feinstein, George T. Kondos, Michael H. Davidson, George L. Bakris, Steven E. Nissen and Kathy Wolski and has published in prestigious journals such as JAMA, Circulation and Journal of the American College of Cardiology.
In The Last Decade
Alfonso Pérez
69 papers receiving 3.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Alfonso Pérez United States | 29 | 2.0k | 1.3k | 997 | 630 | 465 | 69 | 3.7k | ||
| Tamio Teramoto Japan | 38 | 1.7k 0.9× | 878 0.7× | 1.5k 1.5× | 2.6k 4.1× | 696 1.5× | 212 | 5.6k | ||
| Valentine Charlton-Menys United Kingdom | 22 | 2.2k 1.1× | 702 0.6× | 929 0.9× | 2.3k 3.6× | 552 1.2× | 37 | 4.5k | ||
| Maria-Corina Șerban Romania | 39 | 699 0.4× | 760 0.6× | 751 0.8× | 1.6k 2.6× | 472 1.0× | 87 | 4.5k | ||
| Theodosios D. Filippatos Greece | 41 | 2.3k 1.2× | 998 0.8× | 722 0.7× | 1.9k 2.9× | 778 1.7× | 142 | 4.8k | ||
| LeAnne T. Bloedon United States | 24 | 1.7k 0.8× | 773 0.6× | 853 0.9× | 2.5k 4.0× | 381 0.8× | 51 | 4.4k | ||
| Federica Fogacci Italy | 38 | 690 0.4× | 946 0.8× | 589 0.6× | 1.1k 1.7× | 401 0.9× | 149 | 4.0k | ||
| Issam Zineh United States | 32 | 483 0.2× | 867 0.7× | 996 1.0× | 629 1.0× | 291 0.6× | 132 | 4.6k | ||
| David W. Boulton United States | 39 | 2.6k 1.3× | 1.6k 1.2× | 339 0.3× | 1.4k 2.2× | 206 0.4× | 146 | 5.0k | ||
| Olivier Descamps Belgium | 28 | 1.5k 0.8× | 492 0.4× | 1.1k 1.2× | 2.9k 4.6× | 344 0.7× | 86 | 4.5k | ||
| Rommel G. Tirona Canada | 39 | 612 0.3× | 1.1k 0.9× | 321 0.3× | 903 1.4× | 713 1.5× | 99 | 5.7k |
Countries citing papers authored by Alfonso Pérez
Since
Specialization
Citations
This map shows the geographic impact of Alfonso Pérez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfonso Pérez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfonso Pérez more than expected).
Fields of papers citing papers by Alfonso Pérez
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alfonso Pérez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfonso Pérez. The network helps show where Alfonso Pérez may publish in the future.
Co-authorship network of co-authors of Alfonso Pérez
This figure shows the co-authorship network connecting the top 25 collaborators of Alfonso Pérez. A scholar is included among the top collaborators of Alfonso Pérez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfonso Pérez. Alfonso Pérez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Montoro‐García, Silvia, Ángel Bernabé‐García, Irene Luque, et al.. (2024). Monastrol suppresses invasion and metastasis in human colorectal cancer cells by targeting fascin independent of kinesin-Eg5 pathway. Biomedicine & Pharmacotherapy. 175. 116785–116785.
2.
Pérez, Alfonso, Katerina E. Tsitsanou, K.V. Dileep, et al.. (2023). 2D finger-printing and molecular docking studies identified potent mosquito repellents targeting odorant binding protein 1. Insect Biochemistry and Molecular Biology. 157. 103961–103961.
3.
Díaz‐de‐Cerio, Elixabet, Alfonso Pérez, José Antonio Gabaldón, et al.. (2023). Fishing the Targets of Bioactive Compounds from Psidium guajava L. Leaves in the Context of Diabetes. International Journal of Molecular Sciences. 24(6). 5761–5761.
4.
Erdmann, E, Simon Harding, Hung‐Ming Lam, & Alfonso Pérez. (2015). Ten‐year observational follow‐up of PROactive : a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obesity and Metabolism. 18(3). 266–273.
5.
Pérez, Alfonso, et al.. (2015). Latest QSAR study of adenosine A $$_{\mathrm{2B}}$$ 2 B receptor affinity of xanthines and deazaxanthines. Molecular Diversity. 19(4). 975–989.
6.
Pérez, Alfonso, et al.. (2013). Topological structural alerts modulations of mammalian cell mutagenicity for halogenated derivatives. SAR and QSAR in environmental research. 25(1). 17–33.
7.
Zafrilla, Pilar, et al.. (2012). Biomarkers of oxidative stress in patients with wet age related macular degeneration. The journal of nutrition health & aging. 17(3). 219–222.
8.
Pérez, Alfonso, et al.. (2012). Topological sub-structural molecular design approach: Radical scavenging activity. European Journal of Medicinal Chemistry. 49. 86–94.
9.
Nicholls, Stephen J., E. Murat Tuzcu, Kathy Wolski, et al.. (2011). Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. Journal of the American College of Cardiology. 57(2). 153–159.
10.
Sica, Domenic, William B. White, Michael A. Weber, et al.. (2011). Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. Journal of Clinical Hypertension. 13(7). 467–472.
11.
Pérez, Alfonso, et al.. (2010). QSAR models to predict mutagenicity of acrylates, methacrylates and α β
12.
Giles, Thomas D., Uri Elkayam, Mondira Bhattacharya, Alfonso Pérez, & Alan B. Miller. (2010). Comparison of Pioglitazone vs Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease. Congestive Heart Failure. 16(3). 111–117.
13.
Pérez, Alfonso, et al.. (2009). A topological substructural molecular design approach for predicting mutagenesis end-points of α β
14.
Nissen, Steven E., Stephen J. Nicholls, Kathy Wolski, et al.. (2008). Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. JAMA. 299(13). 1561–1561.
15.
Pérez, Alfonso, et al.. (2008). Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity. Bioorganic & Medicinal Chemistry. 16(10). 5720–5732.
16.
Murillo, Serafín, et al.. (2008). Characteristics of physical activity habits in type 2 diabetes patients in Spain. Avances en Diabetología. 24(4). 320–326.
17.
Berhanu, Paulos, Alfonso Pérez, & Shawn Yu. (2006). Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obesity and Metabolism. 9(4). 512–520.
18.
Davidson, Jaime A., et al.. (2005). Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double‐blind, multicentre, randomized study. Diabetes Obesity and Metabolism. 8(2). 164–174.
19.
Rajagopalan, Rukmini, Shrividya Iyer, & Alfonso Pérez. (2004). Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obesity and Metabolism. 7(2). 161–169.
20.
Rajagopalan, Rukmini, Alfonso Pérez, Zhan Ye, Mehmood Khan, & Frederick T. Murray. (2004). Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus. Drugs & Aging. 21(4). 259–271.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tamio Teramoto Breakdown of academic impact, for papers by Valentine Charlton-Menys Breakdown of academic impact, for papers by Maria-Corina Șerban Breakdown of academic impact, for papers by Theodosios D. Filippatos Breakdown of academic impact, for papers by LeAnne T. Bloedon Breakdown of academic impact, for papers by Federica Fogacci Breakdown of academic impact, for papers by Issam Zineh Breakdown of academic impact, for papers by David W. Boulton Breakdown of academic impact, for papers by Olivier Descamps Breakdown of academic impact, for papers by Rommel G. Tirona